Ernst & Young launches Global Pharmaceutical Report 2005

EPP News Bureau - Mumbai

Ernst & Young has released their third annual report on global trends in the pharmaceutical marketplace. The report titled Global Pharmaceutical Report 2005 provides diverse perspectives of industry luminaries from business, academia, government and the clinical fields; and intends to benefit the global pharma industry with enh-anced dialogue between the different stakeholders.

Featuring a compilation of more than 40 articles by thought leaders from around the globe, the report provides insights into diverse topics, such as curbing drug counterfeiting, managing offshoring risks, impact of global indirect taxes and SOX Section 404, issues in drug safety, authorised generics and the growing demand for evidence-based medicines among others.

The report has identified that Indian pharma will hold a competitive advantage in the new product patent regime. ‘‘Any discussion on the global pharmaceutical supply chain can now no longer ignore India’s relevance,’’ said Utkarsh Palnitkar, Health Sciences Industry Practice Leader, Ernst & Young India.

‘‘India is becoming an integral part of the pharma value chain, as large global pharma companies continue to increase their sourcing of APIs, offshoring of clinical development and partnering with domestic companies for new product development and marketing, in India. Over the long term, India is bound to have a larger impact on global pharma’s tax, regulatory and IT environment beyond the obvious impact on its innovation and manufacturing.’’